Prevalence of NAFLD in T2DM Patients

Not Applicable

Active, not recruiting

• Conditions: Type 2 Diabetes; Fatty Liver, Nonalcoholic; T2D; NAFLD
• Interventions: Diagnostic Test: FibroScan

• Registration Number: NCT06445335
• Lead Sponsor: Ziekenhuis Oost-Limburg

Brief Summary

To determine the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).

Detailed Description

Not available

Study Timeline

• Study Start: 2019-03-01
• Status Verified: 2024-05
• Study First Submitted: 2024-05-21
• Study First Submitted QC: 2024-06-03
• Last Update Submitted: 2024-06-03
• Study First Posted: 2024-06-06
• Last Update Posted: 2024-06-06
• Primary Completion: 2024-11-01
• Study Completion: 2024-11-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 385

Inclusion Criteria

• ≥ 18 years of age
• Having type 2 diabetes mellitus (T2DM)
• Written informed consent obtained

Exclusion Criteria

• Excessive alcohol use
• Exclusion of other causes of liver disease and secondary causes of steatosis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
FibroScan	FibroScan	-

Primary Outcome Measures

Name	Time	Method
Prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients	Baseline	To determine the prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients followed at the department of Endocrinology in Ziekenhuis Oost-Limburg (ZOL), Genk, Belgium by means of FibroScan measurements.

Trial Locations

Locations (1)

Ziekenhuis Oost-Limburg; 🇧🇪 Genk, Limburg, Belgium